NADEZHDA DAVIS: Open Payments
NPI 1033269188 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,675 in 65 payments from 8 companies in 2025. Trend: 2023 $2,347 · 2024 $1,586 · 2025 $1,675
Food & beverage: $1,670Education: $5
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 12 | $461 |
| Janssen Pharmaceuticals, Inc | 12 | $334 |
| Teva Pharmaceuticals USA, Inc. | 8 | $258 |
| E.R. Squibb & Sons, L.L.C. | 9 | $230 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $171 |
| Otsuka America Pharmaceutical, Inc. | 4 | $86 |
| Alkermes, Inc. | 3 | $68 |
| Lundbeck LLC | 3 | $67 |
Products named: INGREZZA, INVEGA SUSTENNA, UZEDY, CAPLYTA, COBENFY, ARISTADA, REXULTI, ABILIFY ASIMTUFII.
Industry payments across CA — which companies pay providers there.
